Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 601–700 of 1,001
Teng, X., Wu, B., Liang, Z., Zhang, L., Yang, M., Liu, Z., Liang, Q., & Wang, C. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09922-0 · Cited by 17
Advances in gut microbiota-related treatment strategies for managing colorectal cancer in humans
Bhaskar, R., Cao, K., Singh, C. O., Fang, X., Yang, H., & Dong, W. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0263 · Cited by 17
A clinical primer of the role of gut microbiome in health and disease
Yang, A. L., & Kashyap, P. (2015) · Tropical Gastroenterology · doi:10.7869/tg.238 · Cited by 19
Gloux, K., & Anba‐Mondoloni, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148291 · Cited by 17
Recent Progress in Engineering Human-Associated Microbiomes
Yaung, S. J., Church, G. M., & Wang, H. H. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0554-6_1 · Cited by 19
Self-citationMicrobial Modulation of a Uremic Toxin
Skye, S. M., & Hazen, S. L. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.11.005 · Cited by 19
Sequence editing strategy for improving performance of β-glucuronidase from Aspergillus terreus
Xu, Y., Liu, Y., Rasool, A., Wenwen, E., & Li, C. (2017) · Chemical Engineering Science · doi:10.1016/j.ces.2017.04.011 · Cited by 18
Véziant, J., Poirot, K., Chevarin, C., Cassagnes, L., Sauvanet, P., Chassaing, B., Robin, F., Godfraind, C., Barnich, N., Pezet, D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-031472 · Cited by 19
Ervin, S. M., & Redinbo, M. R. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0155 · Cited by 17
Self-citationMicrobiota and cancer: In vitro and in vivo models to evaluate nanomedicines
Ladaycia, A., Loretz, B., Passirani, C., Lehr, C., & Lepeltier, É. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.015 · Cited by 17
Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights
Bangolo, A., Trivedi, C. P., Jani, I., Pender, S., Khalid, H., Alqinai, B., Intisar, A., Randhawa, K., Moore, J., Deugd, N. D., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i25.3984 · Cited by 17
Li, H., Hou, Z., Zhang, W., Qu, J., Yao, H.-B., & Chen, Y. (2023) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2023.107857 · Cited by 16
Chemical genetic approaches to dissect microbiota mechanisms in health and disease
Yang, X., & Hang, H. C. (2024) · Science · doi:10.1126/science.ado8548 · Cited by 16
Cong, J., Zhu, J., Zhang, C., Li, T., Liu, K., Liu, D., Zhou, N., Jiang, M., Hou, H., & Zhang, X. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01008 · Cited by 16
Role of Microbial Flora and Probiotics in Host Immune Homeostasis
Mishra, P., & Mishra, S. K. (2018) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2018.81018 · Cited by 18
Mahran, E., Keusgen, M., & Morlock, G. E. (2020) · Analytica Chimica Acta X · doi:10.1016/j.acax.2020.100039 · Cited by 21
Bai, Y., Lu, C., Wang, P., Tang, Y.-Q., Wu, D., Zhang, C., Zhou, Q., Yan, R., & Hou, J. (2021) · Food & Function · doi:10.1039/d1fo01748a · Cited by 16
Kaliannan, K., Donnell, S. O., Murphy, K., Stanton, C., Kang, C., Wang, B., Li, X., Bhan, A. K., & Kang, J. X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105332 · Cited by 17
Phong, N. V., Zhao, Y., Min, B. S., Yang, S. Y., & Kim, J. A. (2022) · Metabolites · doi:10.3390/metabo12100938 · Cited by 16
Cui, L., He, N., Yu, S., Pang, H., Zhang, Z., Wang, J., Hao, J., & Li, S. (2023) · Molecules · doi:10.3390/molecules28134984 · Cited by 16
The New Frontier: the Intestinal Microbiome and Surgery
Skowron, K. B., Shogan, B. D., Rubin, D. T., & Hyman, N. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3744-7 · Cited by 16
Pellock, S. J., Walton, W. G., & Redinbo, M. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01285 · Cited by 16
Self-citationAlmandil, N. B., Taha, M., Gollapalli, M. A. S., Rahim, F., Ibrahim, M., Mosaddik, A., & Anouar, E. H. (2019) · BMC Chemistry · doi:10.1186/s13065-019-0522-x · Cited by 16
Bioinformatic Methodologies in Assessing Gut Microbiota
Fox, J. D., Sims, A., Ross, M., Bettag, J., Wilder, A., Natrop, D., Borsotti, A., Kolli, S., Mehta, S., Verma, H., et al. (2024) · Microbiology Research · doi:10.3390/microbiolres15040170 · Cited by 15
Yue, B., Gao, R., Zhao, L., Liu, D., Lv, C., Wang, Z., Ai, F., Zhang, B., Yu, Z., Geng, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202411052 · Cited by 23
Self-citationQi, Q., Zhang, Z., Ji, X., & Wang, D.-Q. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01632 · Cited by 15
The microbiome regulates host metabolic health and diseases through microbial enzymes
Ding, Y., Zhang, Z., Wang, K., & Jiang, C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01195-8 · Cited by 16
Ge, Y., Ma, Y., Zhao, M., Wei, J., Wu, X., Zhang, Z., Yang, H. Y., Lei, H., & Wu, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114699 · Cited by 15
Glucuronic acid confers colonization advantage to enteric pathogens
Rosay, T., Jimenez, A. G., & Sperandio, V. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2400226121 · Cited by 15
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
Lu, C., Liu, D., Wu, Q., Zeng, J., Xiong, Y., & Luo, T. L. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00585-7 · Cited by 15
Gut Microbiota and Liver Injury (I)—Acute Liver Injury
Wu, G., Win, S., Than, T. A., Chen, P., & Kaplowitz, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_3 · Cited by 16
Variant Discovery Using Next-Generation Sequencing and its Future Role in Pharmacogenetics
Russell, L. E., & Schwarz, U. I. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0190 · Cited by 17
The interaction between gut microbiome and anti-tumor drug therapy.
Fu, C., Yang, Z., Yu, J., & Wei, M. (2021) · PubMed · Cited by 21
Therapeutic implications of the gastrointestinal microbiome
Kashyap, P., & Quigley, E. M. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.004 · Cited by 15
Microbiota and cancer: an update
Vallianou, N. G., & Tzortzatou, F. (2019) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1541046 · Cited by 16
Immunomodulatory interplay of the microbiome and therapy of rheumatic diseases
Ostrov, B. E., & Amsterdam, D. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1373828 · Cited by 16
Targeting Bacteria to Improve Cancer Therapy
Patel, A. G., & Kaufmann, S. H. (2010) · Science · doi:10.1126/science.1198310 · Cited by 15
Diarrheal disease and gut microbiome
Ramamurthy, T., Kumari, S., & Ghosh, A. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.08.002 · Cited by 18
The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman, D. D., Hurd, D. E., & Davar, D. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01431-3 · Cited by 14
Xie, W., Sharma, A., Kaushik, H. K., Sharma, L., Nistha, Anwer, M. K., Sachdeva, M., Elossaily, G. M., Zhang, Y., Pillappan, R., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35336 · Cited by 16
Viglioli, M., Rizzo, S. M., Alessandri, G., Fontana, F., Milani, C., Turroni, F., Mancabelli, L., Croci, N., Rivara, S., Vacondio, F., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124663 · Cited by 14
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites
Hou, Y., Wu, H., Zhang, Z., Wang, J., Chen, Q., Lian, C., He, D., Li, Z., Wei, W., Lin, X., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334699 · Cited by 15
Cong, J., Zhang, Y., Xue, Y., Zhang, C., Xu, M., Liu, D., Zhang, R., & Zhu, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583525 · Cited by 14
Wang, P., Wu, R., Jia, Y., Tang, P. P., Wei, B., Zhang, Q., Wang, V. Y., & Yan, R. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.018 · Cited by 14
Transition-State Ensembles Navigate the Pathways of Enzyme Catalysis
Mickert, M. J., & Gorris, H. H. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b02297 · Cited by 14
Strategies for the treatment of colorectal cancer caused by gut microbiota
de Souza, J. B., de Castro, M. C. A. B., & Cavalcanti, I. M. F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120202 · Cited by 15
Butyrate prevents chemotherapy-induced gastrointestinal toxicity and microbial dysbiosis
Cheatham, S. M., Rehman, Z., Arastonejad, M., Kane, R., Ahmad, N., Luffman, N., Harada, H., Zhang, Y., Tyc, K. M., Gewirtz, D. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30385-8 · Cited by 13
Huang, J., Tang, X., Yang, Z., Chen, J., Wang, K., Shi, C., Liu, Z., Wu, M., & Du, Q. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113736 · Cited by 13
Stevanoska, M., Folz, J. S., Beekmann, K., & Aichinger, G. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.04.013 · Cited by 17
Brossier, C., Jardou, M., Janaszkiewicz, A., Firoud, D., Petit, I., Arnion, H., Pinault, É., Sauvage, F., Druilhe, A., Picard, N., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122792 · Cited by 14
Bioengineered human gut-on-a-chip for advancing non-clinical pharmaco-toxicology
Shin, Y. C., Than, N., Park, S. J., & Kim, H. J. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2365254 · Cited by 14
Phong, N. V., Heo, M., Vinh, L. B., Kim, Y. H., & Yang, S. Y. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139135 · Cited by 13
Zhang, S., Hou, R., Sun, C., Huang, Q.-Y., Lin, L., Li, H., Liu, S., Cheng, Y., & Xu, X. (2024) · Environment International · doi:10.1016/j.envint.2024.108882 · Cited by 13
Glieca, S., Quarta, E., Bottari, B., Lal, V., Sonvico, F., & Buttini, F. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2380334 · Cited by 13
Mickoleit, F., Beierl, J. J., Markert, S., Klein, M. A., Stäbler, S. Y., Maier, D. S., & Schüler, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c05588 · Cited by 13
A literature review on large intestinal hyperelastic constitutive modeling
Bhattarai, A., Kowalczyk, W., & Trần, T. N. (2021) · Clinical Biomechanics · doi:10.1016/j.clinbiomech.2021.105445 · Cited by 13
Le, Z., He, Z., Liu, H., Ke, J., Liu, L., Liu, Z., & Chen, Y. (2022) · Biomaterials Science · doi:10.1039/d2bm00540a · Cited by 13
An Insight into the Clinical Application of Gut Microbiota during Anticancer Therapy
Li, W., & Chen, T. (2022) · Advanced Gut & Microbiome Research · doi:10.1155/2022/8183993 · Cited by 16
Potential Role of Host Microbiome in Areca Nut-Associated Carcinogenesis and Addiction
Chen, L., Yuan, F., Chen, S., Li, X., Kong, L., & Zhang, W. (2022) · Molecules · doi:10.3390/molecules27238171 · Cited by 13
Su, J., Dong, J., Kitaguchi, T., Ohmuro‐Matsuyama, Y., & Ueda, H. (2018) · The Analyst · doi:10.1039/c8an00074c · Cited by 13
Zhang, J., Zhang, J., Wang, R., & Jia, Z. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666181019145159 · Cited by 14
Parkinson disease, levodopa and the gut microbiota—when microbiology meets pharmacology
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.14919 · Cited by 13
Separating the microbiome from the hyperbolome
Shanahan, F. (2015) · Genome Medicine · doi:10.1186/s13073-015-0143-5 · Cited by 12
Nguyen, M. K., Nguyen, V. P., Yang, S. Y., Min, B. S., & Kim, J. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107230 · Cited by 12
Gut microbial β-Glucuronidase: A key regulator of endobiotic homeostasis
Ning, L., & Hong, J. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.05.007 · Cited by 12
Emerging gut microbial glycoside hydrolase inhibitors
Kowalewski, M. E., & Redinbo, M. R. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00050e · Cited by 12
Self-citationAgoni, L., Roselletti, E., Marasco, G., Martinelli, C. V., Pericolini, E., & Seta, F. D. (2026) · Microorganisms · doi:10.3390/microorganisms14061327 · Cited by 12
von Schwartzenberg, R. J., & Turnbaugh, P. J. (2015) · Cell · doi:10.1016/j.cell.2015.11.012 · Cited by 15
Lei, L., Xie, X., He, L., Chen, K., Lv, Z., Zhou, B., Li, Y., Hu, W., & Zhou, Z. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-01014-0 · Cited by 12
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance
Mondal, P., & Meeran, S. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10138-7 · Cited by 12
Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers
Mascaretti, F., Haider, S., Amoroso, C., Caprioli, F., Ramai, D., & Ghidini, M. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01021-x · Cited by 12
Haq, I. U., & Akram, F. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.189 · Cited by 12
Chen, Z., Xu, X., Piao, L., Chang, S., Liu, J., & Kong, R. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13655 · Cited by 12
Transforming of Triptolide into Characteristic Metabolites by the Gut Microbiota
Peng, R., Ma, S., Fu, J., Han, P., Pan, L., Zhang, Z., Yu, H., & Wang, Y. (2020) · Molecules · doi:10.3390/molecules25030606 · Cited by 12
Lu, J., Lin, Z., Huang, S., Shen, Y., Jiang, J., & Lin, S. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/7901231 · Cited by 12
RETRACTED ARTICLE: Anti-cancer activity of human gastrointestinal bacteria
Quazi, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01771-3 · Cited by 12
RetractedIqbal, S., Shaikh, N. N., Khan, K. M., Kiran, S., Naz, S., Ul‐Haq, Z., Perveen, S., & Choudhary, M. I. (2022) · Molecules · doi:10.3390/molecules27227786 · Cited by 12
Guan, H.-Y., Wang, X., Wang, S., He, Y., Yue, J.-J., Liao, S., Huang, Y., & Shi, Y. (2017) · RSC Advances · doi:10.1039/c7ra03521g · Cited by 12
Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?
Lu, L., Wu, Y., Zuo, L., Luο, X., & Large, P. J. (2013) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-013-1507-x · Cited by 16
Role of Gut Microbiome in Cancer Treatment
Mishra, V., & Mishra, Y. (2024) · Indian Journal of Microbiology · doi:10.1007/s12088-024-01340-4 · Cited by 12
Synergism of Diet, Genetics, and Microbiome on Health
Das, P., Banka, R., Ghosh, J., Singh, K., Choudhury, S. R., & Koner, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-5528-2.ch006 · Cited by 11
A Small-Molecule Inhibitor of Gut Bacterial Urease Protects the Host from Liver Injury
Richards-Corke, K. C., Jiang, Y., Yeliseyev, V., Zhang, Y., Franzosa, E. A., Wang, Z. A., Abeywardana, M. Y., Cole, P. A., Huttenhower, C., Bry, L., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.3c00556 · Cited by 11
Ying, T., Hu, H., Wu, X.-W., Xu, X.-L., Lv, J., Zhang, S., Wang, H., Hou, W., Wei, B., & Rao, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117571 · Cited by 11
Self-citationSultan, M. H., Zhang, Q., Wang, Y., Xia, Y., & Jia, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5545 · Cited by 11
Chemotherapy modulation by a cancer-associated microbiota metabolite
Martínez‐Martínez, D., Peres, T. V., Gehling, K., Quintaneiro, L. M., Cabrera, C., Cherevatenko, M., Cutty, S. J., Best, L., Μαρίνος, Γ., Zimmerman, J., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101397 · Cited by 12
Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML)
Tian, M., Samarkhazan, H. S., Alemohammad, S. S., Fakhraei, M., Tavakoli, F., Shams, A., & Zeynalabadi, A. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00891-8 · Cited by 11
Recent progress in targeting cancer
Demidenko, Z. N., & McCubrey, J. A. (2011) · Aging · doi:10.18632/aging.100421 · Cited by 11
The Impact of the Host Intestinal Microbiome on Carcinogenesis and the Response to Chemotherapy
Wertman, J. N., Dunn, K. A., & Kulkarni, K. P. (2021) · Future Oncology · doi:10.2217/fon-2021-0087 · Cited by 11
Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)
Huang, X., Mao, L., Hou, S., & Tian, B. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5281 · Cited by 11
Letertre, M. P. M., Bhatt, A. P., Harvey, M., Nicholson, J. K., Wilson, I. D., Redinbo, M. R., & Swann, J. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-21518-4 · Cited by 11
Self-citationSecondary metabolites from the Cordyceps-colonizing fungus Aspergillus versicolor ZJUTE2
Ran, K., Fu, Z., Wu, M., Chen, X., Xu, S., Tong, C., Chen, Y., Zhang, Y., Wang, H., Shan, W., et al. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105501 · Cited by 11
Self-citationTea flavan-3-ols as modulating factors in endoplasmic reticulum function
Révész, K., Tüttõ, A., Szelényi, P., & Konta, L. (2011) · Nutrition Research · doi:10.1016/j.nutres.2011.09.008 · Cited by 12
Microbiology and Ecology Are Vitally Important to Premedical Curricula
Smith, V. H., Rubinstein, R., Park, S., Kelly, L., & Klepac‐Ceraj, V. (2015) · Evolution Medicine and Public Health · doi:10.1093/emph/eov014 · Cited by 15
Microbiota Modulates the Immunomodulatory Effects of Filifolinone on Atlantic Salmon
Parra, M., Espinoza, D., Valdés, N., Vargas, R. A., González, A., Modak, B., & Tello, M. (2020) · Microorganisms · doi:10.3390/microorganisms8091320 · Cited by 12
Endocrine Disruption and the Gut Microbiome
Acharya, K. D., Parakoyi, A. E. R., & Tetel, M. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821985-0.00015-3 · Cited by 11
Sun, C., Tian, X., Feng, L., Wang, C., Li, J., Huo, X., Zhao, W., Ning, J., Yu, Z., Deng, S., et al. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103457 · Cited by 11
Mehmood, K., Moin, A., Hussain, T., Rizvi, S. M. D., Gowda, D., Shakil, S., & Kamal, M. (2021) · Folia Microbiologica · doi:10.1007/s12223-021-00926-5 · Cited by 12
Meds Modify Microbiome, Mediating Their Effects
Koropatkin, N. M., & Martens, E. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.022 · Cited by 11
Baliou, S., Adamaki, M., Spandidos, D. A., Kyriakopoulos, A. M., Christodoulou, I., & Zoumpourlis, V. C. (2018) · World Academy of Sciences Journal · doi:10.3892/wasj.2018.6 · Cited by 11
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.